SynthesisEuropean journal of pediatrics2025
Early kidney damage in children and adolescents with primary arterial hypertension: a systematic review.
Synthesis in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary arterial hypertension (PAH) in children and adolescents is increasingly recognized as a significant health issue that may lead to early kidney damage. This systematic review aims to summarize current evidence on renal impairment in pediatric PAH. A systematic literature search was conducted in the PubMed, CINAHL, and Web of Science databases for studies published in English between 2013 and August 2025, with the final search performed on 28 October 2025. Eligible studies included participants aged 1 month to 17 years with PAH who reported at least one renal outcome, such as glomerular filtration rate (GFR), proteinuria/albuminuria, or other renal biomarkers. Studies including infants (< 1 month), adults (> 17 years), or children with chronic kidney disease or other comorbidities were excluded. Two reviewers independently screened and selected studies based on predefined inclusion and exclusion criteria. Study quality was assessed using the Newcastle-Ottawa Scale. Study characteristics and outcomes were summarized in tables, and key findings were described narratively. A total of 20 studies involving more than 2000 children with PAH were included. Proteinuria and microalbuminuria were the most commonly reported indicators of renal involvement, though evidence of statistical significance varied across studies. Twelve studies reported proteinuria or albuminuria above threshold values in 0.8-36% of participants. For example, Yang et al. reported a statistically significant 25.9% prevalence of albuminuria (p = 0.003). Several studies noted glomerular hyperfiltration, while others reported normal GFR values. Data on renal biomarkers such as cystatin C, β₂-microglobulin, and N-acetyl-β-D-glucosaminidase were limited and showed inconsistent associations with hypertension. Additionally, variations in blood pressure measurement techniques, diagnostic criteria, and population characteristics, including obesity prevalence, contributed to differences across studies.
conclusionEvidence suggests that early kidney damage, particularly albuminuria and changes in GFR, may be present in children with PAH. However, significant variability among studies underscores the need for standardized methodologies and long-term research to clarify the impact of PAH on renal injury in the pediatric population. WHAT IS KNOWN: • PAH in children is increasingly prevalent, closely linked to obesity and lifestyle factors. • Hypertension-related kidney damage is well established in adults, but pediatric data remain limited. WHAT IS NEW: • This review highlights possible early signs of renal involvement in pediatric PAH, including microalbuminuria and glomerular hyperfiltration. • Variability in diagnostic criteria and study designs limits comparability; this review emphasizes the need for standardized, long-term pediatric studies.
Indexed as
Identifiers
41381968What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.